Aridis Pharmaceuticals (NASDAQ:ARDS) Downgraded to Sell at Zacks Investment Research

Share on StockTwits

Zacks Investment Research downgraded shares of Aridis Pharmaceuticals (NASDAQ:ARDS) from a hold rating to a sell rating in a research note issued to investors on Thursday morning, Zacks.com reports.

According to Zacks, “Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. The company’s product pipeline consists of AR-301, AR-105, AR-101, AR-401, AR-201 and AR-501 which are in clinical stages. Aridis Pharmaceuticals, Inc. is based in San Jose, United States. “

A number of other research firms also recently issued reports on ARDS. ValuEngine upgraded shares of Aridis Pharmaceuticals from a hold rating to a buy rating in a research report on Thursday, August 1st. Maxim Group reiterated a buy rating and issued a $25.00 target price on shares of Aridis Pharmaceuticals in a research report on Thursday. Finally, Northland Securities reiterated a buy rating and issued a $40.00 target price on shares of Aridis Pharmaceuticals in a research report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Aridis Pharmaceuticals currently has a consensus rating of Buy and a consensus target price of $27.50.

ARDS stock opened at $7.75 on Thursday. Aridis Pharmaceuticals has a 12-month low of $6.91 and a 12-month high of $13.85. The company has a market cap of $67.02 million and a price-to-earnings ratio of -1.11. The company has a 50 day moving average of $9.46 and a two-hundred day moving average of $9.45.

Aridis Pharmaceuticals (NASDAQ:ARDS) last released its earnings results on Monday, August 12th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.19). Aridis Pharmaceuticals had a negative return on equity of 130.22% and a negative net margin of 660.78%. As a group, analysts expect that Aridis Pharmaceuticals will post -3.78 EPS for the current fiscal year.

About Aridis Pharmaceuticals

Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.

Featured Story: How does equity income fit into an investing strategy?

Get a free copy of the Zacks research report on Aridis Pharmaceuticals (ARDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aridis Pharmaceuticals (NASDAQ:ARDS)

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.